Familial adenomatous polyposis Pipeline

DelveInsight’s, “Familial adenomatous polyposis Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Familial adenomatous polyposis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Familial adenomatous polyposis Understanding

Familial adenomatous polyposis Overview

Familial adenomatous polyposis (FAP) is a rare inherited autosomal dominant disorder caused primarily by mutations in the APC gene. It is characterized by the development of hundreds to thousands of adenomatous polyps in the colon and rectum, typically beginning during adolescence. If left untreated, these polyps almost inevitably progress to colorectal cancer, making early diagnosis, surveillance, and preventive management essential. FAP is also associated with an increased risk of several extracolonic malignancies, including duodenal, gastric, thyroid, and liver cancers.

Familial adenomatous polyposis (FAP) is primarily caused by germline mutations in the APC (adenomatous polyposis coli) tumor suppressor gene, which is inherited in an autosomal dominant manner. These mutations disrupt the regulation of cell growth and differentiation in the intestinal epithelium, leading to the formation of numerous adenomatous polyps in the colon and rectum. Approximately 20–30% of cases arise from de novo APC mutations in individuals with no family history of the disease.

The pathophysiology of familial adenomatous polyposis (FAP) is driven by mutations in the APC tumor suppressor gene, resulting in dysregulation of the Wnt/β-catenin signaling pathway. Loss of APC function leads to the accumulation of β-catenin within cells, promoting uncontrolled cellular proliferation and impaired differentiation of the intestinal epithelium. This process drives the development of numerous adenomatous polyps throughout the colon and rectum, which can progressively acquire additional genetic alterations and ultimately transform into colorectal cancer if left untreated.

Diagnosis of familial adenomatous polyposis (FAP) is based on the identification of numerous adenomatous colorectal polyps through endoscopic evaluation, supported by a detailed family history and clinical assessment. Genetic testing for APC gene mutations is the gold standard for confirming the diagnosis and enables early detection of at-risk family members. Regular colonoscopic surveillance is essential for monitoring disease progression and guiding preventive management.

Treatment of familial adenomatous polyposis (FAP) focuses on preventing colorectal cancer through intensive surveillance and timely surgical intervention. Prophylactic colectomy remains the cornerstone of management for patients with a significant polyp burden, while regular endoscopic monitoring is used to detect and manage residual or upper gastrointestinal polyps. Genetic counseling and lifelong follow-up are essential components of care to reduce cancer risk and monitor for extracolonic manifestations.

"Familial adenomatous polyposis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Familial adenomatous polyposis pipeline landscape is provided which includes the disease overview and Familial adenomatous polyposis treatment guidelines. The assessment part of the report embraces, in depth Familial adenomatous polyposis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Familial adenomatous polyposis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Familial adenomatous polyposis Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Familial adenomatous polyposis R&D. The therapies under development are focused on novel approaches to treat/improve Familial adenomatous polyposis.

Familial adenomatous polyposis Emerging Drugs Analysis

This segment of the Familial adenomatous polyposis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Familial adenomatous polyposis Emerging Drugs

eRapa: Biodexa Pharmaceuticals

eRapa is a proprietary oral formulation of rapamycin (sirolimus) and it acts as an inhibitor of the mammalian target of rapamycin (mTOR), a key signaling pathway involved in cellular growth, proliferation, and metabolism that is frequently overexpressed in FAP-associated polyps. By suppressing mTOR activity, eRapa is designed to reduce polyp growth and burden, potentially delaying disease progression and the need for surgical intervention. The formulation incorporates nanotechnology and pH-sensitive polymers to improve rapamycin bioavailability and pharmacokinetic consistency while minimizing toxicity. In May 2025, the company announced that the European Commission (EC) has granted Orphan Drug Designation for eRapa in familial adenomatous polyposis. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Familial adenomatous polyposis.

Further product details are provided in the report……..

Familial adenomatous polyposis Drug Therapeutic Assessment

This segment of the report provides insights about the different Familial adenomatous polyposis drugs segregated based on following parameters that define the scope of the report, such as:

Major Familial adenomatous polyposis Players in Familial adenomatous polyposis

There are approx. 5+ key companies which are developing the therapies Familial adenomatous polyposis. The companies which have their Familial adenomatous polyposis drug candidates in the most advanced stage, i.e. Phase III include, Biodexa Pharmaceuticals, and others.

Familial adenomatous polyposis Clinical Trial Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Familial adenomatous polyposis Drug Route of Administration

Familial adenomatous polyposis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Familial adenomatous polyposis Product Molecule Type

Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Familial adenomatous polyposis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Familial adenomatous polyposis Clinical Trial Activities

The Familial adenomatous polyposis Pipeline report provides insights into different Familial adenomatous polyposis Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Familial adenomatous polyposis therapeutic drugs key players involved in developing key drugs.

Familial adenomatous polyposis Pipeline Development Activities

The Familial adenomatous polyposis Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Familial adenomatous polyposis drugs.

Familial adenomatous polyposis Report Insights

Familial adenomatous polyposis Pipeline Analysis
Familial adenomatous polyposis Therapeutic Assessment
Familial adenomatous polyposis Unmet Needs
Impact of Familial adenomatous polyposis Drugs

Familial adenomatous polyposis Report Assessment

Familial adenomatous polyposis Pipeline Product Profiles
Familial adenomatous polyposis Therapeutic Assessment
Familial adenomatous polyposis Pipeline Assessment
Familial adenomatous polyposis Inactive drugs assessment
Familial adenomatous polyposis Market Unmet Needs

Key Questions Answered in the Familial adenomatous polyposis Pipeline Report

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Familial adenomatous polyposis drugs?
How many Familial adenomatous polyposis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Familial adenomatous polyposis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Familial adenomatous polyposis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Familial adenomatous polyposis and their status?
What are the key designations that have been granted to the emerging drugs?